Raghavendra A Shamanna Selected Research

olaparib

1/2019

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raghavendra A Shamanna Research Topics

Disease

4	Genomic Instability 01/2017 - 11/2014
3	Neoplasms (Cancer) 01/2019 - 01/2016
2	Rothmund-Thomson Syndrome (Syndrome, Rothmund-Thomson) 12/2017 - 01/2016
1	Mitochondrial Diseases (Mitochondrial Disease) 10/2016
1	Breast Neoplasms (Breast Cancer) 03/2016
1	Werner Syndrome (Werner's Syndrome) 03/2016
1	Inborn Genetic Diseases (Disease, Hereditary) 11/2014
1	Cognitive Dysfunction 06/2014
1	Disease Progression 01/2014
1	Infections 07/2011
1	Latent Infection 07/2011

Drug/Important Bio-Agent (IBA)

4	RecQ HelicasesIBA 01/2017 - 11/2014
4	Proteins (Proteins, Gene)FDA Link 03/2016 - 07/2011
2	DNA (Deoxyribonucleic Acid)IBA 03/2016 - 11/2014
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019
1	olaparibIBA 01/2019
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 12/2017
1	NAD (NADH)IBA 10/2016
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 03/2016
1	CamptothecinIBA 03/2016
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 03/2016
1	Tissue ExtractsIBA 06/2014
1	AntibodiesIBA 01/2014
1	VaccinesIBA 01/2014
1	Cyclin TIBA 07/2011

Therapy/Procedure

1	Therapeutics 01/2019
1	Drug Therapy (Chemotherapy) 03/2016